Alembic intros fluphenazine hydrochloride tabletsFluphenazine hydrochloride tablets are are indicated in the management of manifestations of psychotic disorders. AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERAThe Association for Accessible Medicines and its Biosimilars Council oppose passage of the PREVAIL Act and the PERA Act. Former FDA commissioner Scott Gottlieb will keynote AAM's annual meeting Scott Gottlieb also will moderate the CEOs Unplugged session, where healthcare executives will share their candid insights and industry perspectives. AAM, Biosimilar Council host patent abuse Congressional briefing AAM, The ERISA Industry Committee and Transparency-Rx sent a letter to Congressional leaders urging prompt legislative action. Hikma completes Xellia acquisition The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities and an R&D center in Zagreb, Croatia. Alimera Sciences takes legal action against ANI Pharmaceuticals to enforce merger agreement Alimera’s lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by the merger agreement. Amneal, Shilpa receive FDA nod for Boruzu Boruzu is a ready-to-use oncology treatment used for multiple myeloma and mantle cell lymphoma. Alembic intros generic Luxiq Foam The foam treats inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Evernorth to offer Stelara biosimilar at $0 out of pocket for patients early next year The estimated savings for individual Accredo patients is around $4,000 per year. Former FDA commissioner Janet Woodcock to headline AAM’s GRx+Biosims conference The conference takes place in Rockland, Md., Oct. 21-23. First Previous 7 8 9 10 11 Next Last
